Tracing PAH Emission in lambda-Orionis Using COBE/DIRBE Data

We use archival COBE/DIRBE data to construct a map of polycyclic aromatic hydrocarbon (PAH) emission in the &lambda;-Orionis region. The presence of the 3.3 &mu;m PAH feature within the DIRBE 3.5 &mu;m band and the corresponding lack of significant PAH spectral features in the adjacent DIRBE bands (1.25, 2.2, and 4.9 &mu;m) enable estimation of the PAH contribution to the 3.5 &mu;m data. Having the shortest wavelength of known PAH features, the 3.3 &mu;m feature probes the smallest PAHs, which are also the leading candidates for carriers of anomalous microwave emission (AME). We use this map to investigate the association between the AME and the emission from PAH molecules. We find that the spatial correlation in &lambda;-Orionis is higher between AME and far-infrared dust emission (as represented by the DIRBE 240 &mu;m map) than it is between our PAH map and AME. This finding, in agreement with previous studies using PAH features at longer wavelengths, is in tension with the hypothesis that AME is due to spinning PAHs. However, the expected correlation between mid-infrared and microwave emission could potentially be degraded by different sensitivities of each emission mechanism to local environmental conditions even if PAHs are the carriers of both. &nbsp;</p

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma

BACKGROUND: We wished to evaluate the clinical response following ATP-Tumor Chemosensitivity Assay (ATP-TCA) directed salvage chemotherapy in a series of UK patients with advanced ovarian cancer. The results are compared with that of a similar assay used in a different country in terms of evaluability and clinical endpoints. METHODS: From November 1998 to November 2001, 46 patients with pre-treated, advanced ovarian cancer were given a total of 56 courses of chemotherapy based on in-vitro ATP-TCA responses obtained from fresh tumor samples or ascites. Forty-four patients were evaluable for results. Of these, 18 patients had clinically platinum resistant disease (relapse < 6 months after first course of chemotherapy). There was evidence of cisplatin resistance in 31 patients from their first ATP-TCA. Response to treatment was assessed by radiology, clinical assessment and tumor marker level (CA 125). RESULTS: The overall response rate was 59% (33/56) per course of chemotherapy, including 12 complete responses, 21 partial responses, 6 with stable disease, and 15 with progressive disease. Two patients were not evaluable for response having received just one cycle of chemotherapy: if these were excluded the response rate is 61%. Fifteen patients are still alive. Median progression free survival (PFS) was 6.6 months per course of chemotherapy; median overall survival (OAS) for each patient following the start of TCA-directed therapy was 10.4 months (95% confidence interval 7.9-12.8 months). CONCLUSION: The results show similar response rates to previous studies using ATP-TCA directed therapy in recurrent ovarian cancer. The assay shows high evaluability and this study adds weight to the reproducibility of results from different centre

Dominance of the CD4 + T helper cell response during acute resolving hepatitis A virus infection

CD4+ T cells play a dominant role in control of acute HAV infection in chimpanzees.Hepatitis A virus (HAV) infection typically resolves within 4–7 wk but symptomatic relapse occurs in up to 20% of cases. Immune mechanisms that terminate acute HAV infection, and prevent a relapse of virus replication and liver disease, are unknown. Here, patterns of T cell immunity, virus replication, and hepatocellular injury were studied in two HAV-infected chimpanzees. HAV-specific CD8+ T cells were either not detected in the blood or failed to display effector function until after viremia and hepatitis began to subside. The function of CD8+ T cells improved slowly as the cells acquired a memory phenotype but was largely restricted to production of IFN-γ. In contrast, CD4+ T cells produced multiple cytokines when viremia first declined. Moreover, only CD4+ T cells responded during a transient resurgence of fecal HAV shedding. This helper response then contracted slowly over several months as HAV genomes were eliminated from liver. The findings indicate a dominant role for CD4+ T cells in the termination of HAV infection and, possibly, surveillance of an intrahepatic reservoir of HAV genomes that decays slowly. Rapid contraction or failure to sustain such a CD4+ T cell response after resolution of symptoms could increase the risk of relapsing hepatitis A

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

The Arts: The Voice of the People

The University Committee for Diversity, Equity and Inclusion, in partnership with President Christopher Callahan, presents this series of dialogues designed to offer students an enriched co-curricular experience via participating in dialogues with influential citizen leaders from across the country. The dialogues address the social, cultural and structural inequities in our society and help educate, engage and empower individuals to become transformative leaders in the fight for social justice

The Arts: The Voice of the People

The University Committee for Diversity, Equity and Inclusion, in partnership with President Christopher Callahan, presents this series of dialogues designed to offer students an enriched co-curricular experience via participating in dialogues with influential citizen leaders from across the country. The dialogues address the social, cultural and structural inequities in our society and help educate, engage and empower individuals to become transformative leaders in the fight for social justice

Constraints on the Optical Depth to Reionization from Balloon-Borne CMB Measurements

We assess the uncertainty with which a balloon-borne experiment, nominally called Tau Surveyor ($\tau$S), can measure the optical depth to reionization $\sigma(\tau)$ with one mid-latitude flight and given realistic constraints of instrument noise and foreground emissions. Using a $\tau$S fiducial design with six frequency bands between 150 and 380 GHz with white and uniform map noise of 7 $\mu$K arcmin and including Planck 's 30 and 44~GHz data we assess the error $\sigma(\tau)$ achieved with three foreground models and as a function of sky fraction f$_{\rm sky}$ between 40% and 54%. We carry out the analysis using both parametric and blind foreground separation techniques. We compare $\sigma(\tau)$ values to those obtained with low frequency and high frequency versions of the experiment called $\tau$S-lf and $\tau$S-hf that have only four and up to eight frequency bands with narrower and wider frequency coverage, respectively. We find that with $\tau$S the lowest constraint is $\sigma(\tau)=0.0034$, obtained for f$_{\rm sky}$=54%. $\sigma(\tau)$ is larger, in some cases by more than a factor of 2, for smaller sky fractions, with $\tau$S-lf, or as a function of foreground model. The $\tau$S-hf configuration does not lead to significantly tighter constraints. Exclusion of the 30 and 44 GHz data, which give information about synchrotron emission, leads to significant $\tau$ mis-estimates. Decreasing noise by an ambitious factor of 10 while keeping f$_{\rm sky}$=40% gives $\sigma(\tau) =0.0031$. The combination of $\sigma(\tau) =0.0034$, BAO data from DESI, and future CMB B-mode lensing data from CMB-S3/S4 experiments could give $\sigma(\sum m_{\nu}) = 17$ meV.Comment: 19 pages, 7 Figures, submitted to Ap